Compositions for Diagnosis and Treatment of Inflammation

Abstract

Compositions including an fatty acid, such as an odd chain fatty acid or a very long even chain fatty acid, and salts and derivatives thereof, and methods for treatment and prophylaxis of conditions related to inflammation and conditions related to inflammation, including anemia of chronic disease, insulin resistance, metabolic syndrome, autoimmune disease, hypertension, diabetes, nonalcoholic fatty liver disease, cardiovascular disease, cancer, aging, neurodegenerative diseases, including Alzheimer's disease and other forms of dementia, and other related conditions, and other related conditions.

What is claimed is: 
     
         1 . A pharmaceutical composition for treatment of inflammation or conditions related to inflammation, wherein the conditions related to inflammation are selected from the group consisting of anemia of chronic disease, insulin resistance, metabolic syndrome, autoimmune disease, hypertension, diabetes, nonalcoholic fatty liver disease, cardiovascular disease, cancer, aging, neurodegenerative diseases, Alzheimer's disease, and dementia comprising:
 one or more fatty acids, or pharmaceutically acceptable salts thereof, wherein the one or more fatty acids are selected from the group consisting of odd chain fatty acids and very long even chain fatty acids; and   a pharmaceutically acceptable carrier.   
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein the one or more fatty acids is heptadecanoic acid or pentadecanoic acid. 
     
     
         3 . The pharmaceutical composition of any one of  claim 1  or  2 , wherein the composition is substantially free from even chain fatty acids. 
     
     
         4 . The pharmaceutical composition of  claim 1 , wherein the one or more fatty acids is behenic acid or lignoceric acid. 
     
     
         5 . The pharmaceutical composition of  claim 1 , wherein the composition comprises at least one odd chain fatty acid and at least one very long even chain fatty acid. 
     
     
         6 . The pharmaceutical composition of  claim 1 , wherein the one or more fatty acids comprises heptadecanoic acid and behenic acid. 
     
     
         7 . The pharmaceutical composition of any one of  claims 1  through  6 , wherein the composition is in a unit dosage form. 
     
     
         8 . The pharmaceutical composition of any one of  claims 1  through  7 , configured for administration of from 2.5 mg to 11 mg, per 1 kg of body weight, of the one or more fatty acids or pharmaceutically acceptable salts thereof to a patient. 
     
     
         9 . The pharmaceutical composition of any one of  claims 1  through  8 , configured for administration once per day. 
     
     
         10 . The pharmaceutical composition of any one of  claims 1  through  9 , comprising from 0.01 mg to 10000 mg of the one or more fatty acids or pharmaceutically acceptable salts thereof. 
     
     
         11 . Use of a pharmaceutical composition of any one of  claims 1  through  10 , in the manufacture of a medicament for treatment or prophylaxis of inflammation and conditions related to inflammation, wherein the conditions related to inflammation are selected from the group consisting of anemia of chronic disease, insulin resistance, metabolic syndrome, autoimmune disease, hypertension, diabetes, nonalcoholic fatty liver disease, cardiovascular disease, cancer, aging, neurodegenerative diseases, Alzheimer's disease, and dementia. 
     
     
         12 . The use of  claim 11 , in the manufacture of a medicament for treatment or prophylaxis of inflammation. 
     
     
         13 . The use of  claim 12 , wherein the pharmaceutical composition is configured to modulate a marker of inflammation or a symptom of inflammation. 
     
     
         14 . The use of  claim 13 , wherein the marker of inflammation is selected from the group consisting of odd chain fatty acid percentage, serum concentration of an odd chain fatty acid, red blood cell membrane concentration of an odd chain fatty acid, serum total odd chain fatty acids, red blood cell membrane total odd chain fatty acids, serum ferritin, erythrocyte sedimentation rate, serum alkaline phosphatase, serum CRP, IL-6, TNFα, c-Jun N-terminal kinase, ATM and monocyte-chemoattractant protein-1. 
     
     
         15 . The use of any one of  claims 11  through  14 , wherein the pharmaceutical composition is configured to increase a serum concentration or a red blood cell membrane concentration of the one or more fatty acids by at least about 0.001×10 −4  M above a pretreatment value.